Adamas Pharmaceuticals Inc
ADMSDelisted Nov 24, 2021- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001328143
Adamas Pharmaceuticals Inc was delisted on Nov 24, 2021; its insiders filed their last Form 4 on Nov 24, 2021; 63 institutions reported holding it in 13F filings for Q3 2021, worth $147.6M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Adamas Pharmaceuticals Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Adamas Pharmaceuticals Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Demski Martha J | Director | 0 | Nov 24, 2021 | 0 |
| Richo Anna | Director | 0 | Nov 24, 2021 | 0 |
| Bigham Michael | Director | 0 | Nov 24, 2021 | 0 |
| Mahoney David L | Director | 0Indirect | Nov 24, 2021 | 0 |
| MacPhee John A | Director | 0 | Nov 24, 2021 | 0 |
| Ericson William W. | Director, 10% Owner | 0Indirect | Nov 24, 2021 | 0 |
| McFarlane Neil F. | Chief Executive Officer | 0 | Nov 24, 2021 | 0 |
| Prentiss Christopher B | Chief Financial Officer | 0 | Nov 24, 2021 | 0 |
| Shreedhar Vijay | Chief Commercial Officer | 0 | Nov 24, 2021 | 0 |
| Papapetropoulos Spyridon | Director | 0 | Nov 24, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
No insider trades match these filters.